Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbohydrate sulfotransferase 14 (CHST14) is an enzyme responsible for transferring sulfate groups to the C-4 hydroxyl of N-acetyl-D-galactosamine residues in dermatan sulfate, a glycosaminoglycan critical for extracellular matrix integrity in tissues such as skin, tendons, cartilage, and vascular walls. CHST14-mediated sulfation is essential for dermatan sulfate biosynthesis, proper collagen fibril assembly, and structural resilience of connective tissue. Mutations in the CHST14 gene cause near-complete absence of dermatan sulfate, leading to deficient collagen organization and the clinical manifestations of musculocontractural Ehlers–Danlos syndrome (mcEDS), characterized by multisystem fragility, congenital malformations, and progressive tissue dysfunction. No drugs are currently described as targeting CHST14; its major clinical relevance is as a genetic cause of mcEDS and a critical enzyme for extracellular matrix maintenance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbohydrate sulfotransferase 14 (CHST14).